Table 1.
Clinical characteristics in all atrial fibrillation (AF) patients.
| Variables |
Recurrence (n = 43) |
No recurrence (n = 167) |
P-value |
|---|---|---|---|
| Age (years) | 57.74 ± 11.45 | 58.49 ± 9.95 | 0.674 |
| Male (n, %) | 26 (60.5%) | 117 (70.1%) | 0.271 |
| History of AF (months) | 4.84 ± 4.17 | 4.76 ± 4.86 | 0.837 |
| Persistent AF (n, %) | 33 (57.9%) | 84 (54.9%) | 0.756 |
| Smoking (n, %) | 15 (34.9%) | 47 (28.1%) | 0.454 |
| Medical history | |||
| Hyperlipidemia (n, %) | 14 (32.6%) | 38 (22.8%) | 0.234 |
| Hypertension (n, %) | 20 (46.5%) | 68 (40.7%) | 0.494 |
| T2DM (n, %) | 2 (4.7%) | 24 (14.4%) | 0.118 |
| Medication | |||
| VKA (n, %) | 14 (32.6%) | 35 (21.0%) | 0.156 |
| Amiodarone (n, %) | 22 (51.2%) | 92 (55.1%) | 0.732 |
| Beta blockers (n, %) | 10 (23.3%) | 18 (10.8%) | 0.043 |
| ACEI (n, %) | 3 (7.0%) | 6 (3.6%) | 0.394 |
| Lab tests of plasma | |||
| sST2 (ng/ml) | 38.65 ± 17.78 | 32.44 ± 10.34 | 0.033 |
| Cre (μmol/L) | 79.00 ± 47.71 | 71.98 ± 14.27 | 0.346 |
| UA (μmol/L) | 366.43 ± 122.69 | 360.71 ± 79.97 | 0.756 |
| FBG (g/L) | 5.82 ± 1.42 | 5.91 ± 1.17 | 0.673 |
| TC (mmol/L) | 4.78 ± 1.04 | 4.77 ± 1.08 | 0.982 |
| HDL (mmol/L) | 1.25 ± 0.26 | 1.23 ± 0.25 | 0.603 |
| HCY (μmol/L) | 12.83 ± 5.79 | 14.59 ± 7.92 | 0.177 |
| TSH (mU/L) | 2.37 ± 1.84 | 2.37 ± 1.78 | 0.988 |
| Echocardiography | |||
| LVEF (%) | 63.38 ± 6.31 | 61.60 ± 7.11 | 0.137 |
| LAVI (ml/m2) | 30.74 ± 7.54 | 27.29 ± 7.76 | 0.009 |
| Ablation time (min) | 88.56 ± 20.74 | 94.59 ± 24.23 | 0.136 |
T2DM, type 2 diabetes mellitus; VKA, vitamin K antagonist; ACEI, angiotensin-converting enzyme inhibitors; sST2, soluble suppression of tumorigenicity 2; Cre, creatinine; UA, uric acid; FBG, fibrinogen; TC, total cholesterol; HDL, high-density lipoprotein; HCY, homocysteine; TSH, thyroid stimulating hormone; LVEF, left ventricular ejection fraction; LAVI, left atrial volume index.